• Publications
  • Influence
Art-175 Is a Highly Efficient Antibacterial against Multidrug-Resistant Strains and Persisters of Pseudomonas aeruginosa
TLDR
Art-175 is a novel antibacterial that is well suited for a broad range of applications in hygiene and veterinary and human medicine, with a unique potential to target persister-driven chronic infections. Expand
Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii
TLDR
It is reported that Art-175 is highly bactericidal against stationary-phase cells of multidrug-resistant Acinetobacter baumannii, even resulting in a complete elimination of large inocula, and represents a highly active Artilysin against two of the most life-threatening pathogens of the order Pseudomonadales. Expand
Fighting bacterial persistence: Current and emerging anti-persister strategies and therapeutics.
TLDR
This review presents a comprehensive overview of anti- Persister molecules and strategies described in literature to date and offers perspectives on potential anti-persistence targets and methods for the development of future therapies. Expand
Repurposing Toremifene for Treatment of Oral Bacterial Infections
TLDR
The results suggest that the FDA-approved anticancer agent toremifene is a suitable candidate for further investigation for the development of new treatment strategies for oral bacterial infections. Expand
A putative de-N-acetylase of the PIG-L superfamily affects fluoroquinolone tolerance in Pseudomonas aeruginosa.
TLDR
DnpA (de-N-acetylase involved in persistence) is presented as a new gene involved in noninherited fluoroquinolone tolerance in P. aeruginosa persistence and site-directed mutagenesis suggests that this enzymatic activity is essential for DnpA-mediated persistence. Expand
Identification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a Novel Antibacterial Compound Active against Persisters of Pseudomonas aeruginosa
TLDR
A novel antipersister compound active against P. aeruginosa is identified with promising applications for the design of novel, case-specific combination therapies in the fight against chronic infections. Expand
Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3-Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models
TLDR
The broad-spectrum activity of SPI009 is demonstrated, combined with different classes of antibiotics, against the clinically relevant ESKAPE pathogens Enterobacter aerogenes, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii and Burkholderia cenocepacia and Escherichia coli. Expand
1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol Kills Pseudomonas aeruginosa through Extensive Membrane Damage
TLDR
The results demonstrate the extensive membrane-damaging activity of SPI009 and confirm its clinical potential in the development of novel anti-persister therapies and the mode of action of this novel compound using several parallel approaches. Expand
A Whole-Cell-Based High-Throughput Screening Method to Identify Molecules Targeting Pseudomonas aeruginosa Persister Cells.
TLDR
A top-down large-scale screening method capable of specifically identifying small molecule compounds that, in combination with conventional antibiotics, significantly reduce the persister fraction in Pseudomonas aeruginosa is described. Expand
...
1
2
...